{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:15:42Z","timestamp":1788419742305,"version":"build-2803163510"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poliomyelitis remains a public health concern in select regions. Sabin strain-derived inactivated poliovirus vaccine (sIPV) offers a potentially safer and cost-effective alternative to conventional IPV (cIPV) for adult booster immunization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically review and meta-analyze evidence on the safety of sIPV in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Cochrane, and Scopus through January 2026 for randomized controlled trials comparing sIPV with cIPV\/w-IPV or placebo in adults. Safety outcomes included local and systemic adverse events: pain, erythema, induration, fever, headache, malaise, and allergic reactions. Data extraction and risk of bias assessment were independently performed. Meta-analysis was conducted using random-effects models in RevMan 5.4, reporting risk ratios (RR) with 95% confidence intervals (CI). Evidence certainty was assessed using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four trials encompassing 70\u2013340 adults were included. Pooled analyses demonstrated no statistically significant differences in any adverse events between sIPV and cIPV: pain (RR 1.57, 95% CI 0.98\u20132.50), erythema (RR 1.54, 95% CI 0.64\u20133.69), induration (RR 0.33, 95% CI 0.04\u20133.06), fever (RR 0.96, 95% CI 0.39\u20132.33), headache (RR 0.70, 95% CI 0.21\u20132.37), and malaise (RR 0.75, 95% CI 0.17\u20133.27). Heterogeneity was negligible (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). Overall, adverse events were mild, transient, and comparable across vaccines and most included trials reported no serious adverse events (SAEs), indicating a favorable safety profile. Certainty of evidence was low to very low due to small sample sizes and imprecision.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>sIPV demonstrates a safety profile comparable to conventional IPV in adult booster recipients, supporting its use as a viable alternative in polio eradication strategies. Further large-scale and long-term studies are warranted to confirm these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>identifier: CRD420261329648.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1883550","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:40:51Z","timestamp":1788417651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of Sabin-derived inactivated poliovirus vaccine in adult booster recipients: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Muhammad","family":"Hussain","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Dow University of Health Sciences","place":["Karachi, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hassan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dow University of Health Sciences","place":["Karachi, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hannan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dow University of Health Sciences","place":["Karachi, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arham","family":"Kamil","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dow University of Health Sciences","place":["Karachi, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Tayyab","family":"Azam","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dow University of Health Sciences","place":["Karachi, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain Ul Abideen","family":"Shahid","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dow University of Health Sciences","place":["Karachi, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasibullah","family":"Aminpoor","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kabul University of Medical Sciences \u201cAbu Ali Ibn Sina\u201d","place":["Kabul, Afghanistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhaylah","family":"Gore","sequence":"additional","affiliation":[{"name":"Saint Georges University Medical School","place":["St. George's, Grenada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center","place":["Neptune, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guseva","sequence":"additional","affiliation":[{"name":"Russian University of Medicine","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","first-page":"249","article-title":"Apparent global interruption of wild poliovirus type 2 transmission","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B2","first-page":"1031","article-title":"Possible eradication of wild poliovirus type 3\u2014worldwide, 2012","volume":"63","author":"Kew","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1128\/JVI.02122-08","article-title":"Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance","volume":"83","author":"Yakovenko","year":"2009","journal-title":"J Virol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2154100","DOI":"10.1080\/21645515.2022.2154100","article-title":"Current and nextgeneration formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication","volume":"18","author":"Kumar","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.ad","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B10","article-title":"Version 5","author":"Review","year":"2020"},{"key":"B11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/vaccines9060565","article-title":"Immunogenicity and safety of inactivated Sabin-strain polio vaccine \u201cPoliovacSin\u201d: clinical trials phase I and II","volume":"9","author":"Piniaeva","year":"2021","journal-title":"Vaccines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1016\/j.vaccine.2020.05.081","article-title":"Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: a randomized, observer-blind, controlled phase 1\/2 trial","volume":"38","author":"Cramer","year":"2020","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1016\/j.vaccine.2014.07.109","article-title":"Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I trial in healthy adults in Cuba","volume":"32","author":"Resik","year":"2014","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1016\/j.vaccine.2013.09.021","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults","volume":"31","author":"Verdijk","year":"2013","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.1093\/clinids\/6.Supplement_2.S361","article-title":"Mucosal immune response to poliovirus vaccines in childhood","volume":"6","author":"Ogra","year":"1984","journal-title":"Rev Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/21645515.2020.1812315","article-title":"Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER. C6\u00ae cell-line: a phase 1 randomized controlled trial in adults","volume":"17","author":"Leroux-Roels","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/14760584.2020.1800458","article-title":"Safety profile of Infanrix hexa\u221217 years of GSK's passive post-marketing surveillance","volume":"19","author":"Puente","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1016\/j.vaccine.2020.05.081","article-title":"Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: a randomized, observer-blind, controlled phase 1\/2 trial","volume":"38","author":"Asturias","year":"2020","journal-title":"Vaccine"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1883550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:40:53Z","timestamp":1788417653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1883550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":18,"alternative-id":["10.3389\/fpubh.2026.1883550"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1883550","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1883550"}}